Cannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity
Gibson CL, Bassir Nia A, Spriggs SA, DeFrancisco D, Swift A, Perkel C, Zhong X, Mazumdar M, Fernandez N, Patel M, Kim-Schulze S, Hurd YL. Cannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity. Psychiatry Research 2020, 293: 113380. PMID: 32818918, PMCID: PMC8292796, DOI: 10.1016/j.psychres.2020.113380.Peer-Reviewed Original ResearchConceptsInterleukin-6Psychosis severityCannabinoid useCannabis useIL-6 levelsCommon underlying pathologyPANSS total scoreChronic psychotic disordersRisk of psychosisPsychiatric emergency roomNegative Syndrome ScalePsychotic symptom severityInflammatory alterationsInflammatory markersInflammatory disturbancesAcute psychosisInflammatory abnormalitiesNata medicationUnderlying pathologyEmergency roomInflammatory levelsPANSS scoresPsychiatric unitUnadjusted modelsPsychotic disorders